Global Iron-Deficiency Anemia Therapy Market, By Therapy (Parenteral Iron Therapy, Oral Iron Therapy), Therapy Areas (Inflammatory Bowel Disease, Renal, Obstetrics, and Gynecology, Congestive Heart Failure (CHF), Oncology, Others) Population (Adults, Pediatric, Geriatric), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Iron-Deficiency Anemia Therapy Market Analysis and Size
The market for iron deficiency anemia therapy is expected to expand quickly during the coming years. The World Health Organization estimates that between 1.5 and 1.74 billion individuals worldwide suffer from anemia, with iron deficiency accounting for 50% of all cases. The rising incidence of iron deficiency anemia is anticipated to be favorable for the global market for therapies for the condition.
Data Bridge Market Research analyses that the iron-deficiency anemia therapy market, which is USD 3710.61 million in 2022, is expected to reach USD 13,208.89 million by 2030, at a CAGR of 17.2% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Iron-Deficiency Anemia Therapy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Therapy (Parenteral Iron Therapy, Oral Iron Therapy), Therapy Areas (Inflammatory Bowel Disease, Renal, Obstetrics and Gynecology, Congestive Heart Failure (CHF), Oncology, Others) Population (Adults, Pediatric, Geriatric), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Fresenius SE & Co. KGaA (Germany), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Lupin (India), ViforPharma Ltd. (Switzerland), AMAG Pharmaceuticals (U.S.), Akebia Therapeutics, INC. (U.S.), CHO-A Pharmaceutical CO., LTD. (South Korea), Orion Corporation (Finland), Pharmacosmos A/S (Denmark), Shield Therapeutics (U.K.), Advanz Pharmaceutical (U.K.), Alkem Labs (India), Zydus Cadila (India), Hikma Pharmaceuticals PLC (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Iron-deficiency anemia can be treated or prevented with the use of iron-deficiency of foods such as fruits, meat, vegetables, and cereals high in iron. Iron deficiency can be prevented by vitamin C consumption. An inadequate number of healthy red blood cells is a sign of anemia. RBCs give human tissues oxygen. Hemoglobin formation depends on iron, which is present in red blood cells. A low hemoglobin level suggests that the body is not getting enough oxygen. Maintaining a healthy iron level is essential.
Iron-Deficiency Anemia Therapy Market Dynamics
Drivers
• Increasing prevalence of iron deficiency anemia (IDA) will bolster the market growth
Iron deficiency anemia (IDA) is more common than average in developing nations. For instance, a 2017 study by researchers at the Indira Gandhi Institute of Medical Sciences in Bihar, India, found that IDA affected 50% of the adolescent girls polled for the study. 3.3% of them had severe anemia. These startling figures are primarily attributable to inadequate iron intake from regular food sources and blood loss during menstruation and pregnancy. Treatments for iron deficiency anemia may be essential in giving girls and other vulnerable groups the nutrients they need to avoid developing an anemic. Additionally, these treatments can aid in reducing the negative consequences of IDA and improve the health of those affected.
• Growing research and clinical activities will drive the market growth
The popularity of oral iron therapy is predicted to rise, fuelling the segment's expansion, as more studies are coming out in favor of its use as an intravenous treatment alternative in hospital settings. For instance, oral iron supplementation has been regarded as the main treatment for iron deficiency anaemia in children that affects their growth and development, according to the most recent study published by the IRESPUB Journal of Life Sciences in January 2022 and titled "Oral iron formulae for treatment of iron deficiency anemia: a comparative study." But this accelerates the market's expansion.
Opportunities
- An increase in anemia cases will act as an opportunity
Especially in women and children, iron deficiency anemia is becoming more common due to inadequate dietary iron intake and excessive red blood cell loss. This can cause developmental disorders in developing fetuses in pregnant women and growing children, respectively. According to observations, in 2020, anemia was discovered in roughly 53% of women. According to the National Heart, Lung, and Blood Institute's records, 3 million people in North America are estimated to have anemia. One of the main factors influencing the growth of the iron-deficiency anemia therapy market is the rising prevalence of target diseases such as autoimmune diseases, rheumatoid arthritis, renal problems, liver disorders, cancer, thyroid diseases, and inflammatory bowel diseases.
• Increasing incidence of cancer is a promising opportunity
Iron deficiency anemia is becoming more common among cancer patients. Bone cancer, cervical cancer, blood cancer, colon cancer, and prostate cancer are common cancers that are frequently linked to anemia. Among solid tumors, lung and breast tumors have been identified as having the highest anemic prevalence. Anemia is brought on by abnormal blood cells produced by hematologic malignancies such as lymphoma, leukemia, and multiple myeloma. These diseases impair the immune system. Anemia in cancer patients is also made worse by cancer therapies like chemotherapy and radiation. As a result, the market has additional opportunities.
Restraints/Challenges
- The serious effects of iron supplements will hamper the market growth
Consuming iron-containing medications has only a few minor negative effects. Digestive issues like nausea, vomiting, stomach aches and constipation are typical side effects, as well as problems with appetite. Along with exhaustion, weakness, shallow or quick breathing, bluish skin, convulsions, pale skin, or fingernails, these medicines can also induce overdose symptoms. Because of this, the market expansion is hindered.
This iron-deficiency anemia therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the iron-deficiency anemia therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2021, Sandoz announced the launch of Ferumoxytol Injection, the first generic high-dose intravenous iron. This medication is used to treat anemia caused by iron deficiency in U.S. patients. IDA in adults with an aversion to oral iron, a poor reaction to oral iron, or chronic renal disease is treatable with ferumoxytol, a generic version of AMAG Pharmaceuticals' Feraheme.
- In 2022, The Drug Controller General of India granted approval to Zydus' New Drug Application (NDA) for Oxemia. Oxemia is an oral, small-molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) used to treat anemia linked to chronic kidney disease (CKD).
Global Iron-Deficiency Anemia Therapy Market Scope
The iron-deficiency anemia therapy market is segmented on the basis of therapy, therapy areas, population, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapy
- Parenteral Iron Therapy
- Oral Iron Therapy
Therapy Areas
- Inflammatory Bowel Disease
- Renal
- Obstetrics and Gynecology
- Congestive Heart Failure (CHF)
- Oncology
- Others
Population
- Adults
- Pediatric
- Geriatric
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Iron-Deficiency Anemia Therapy Market Regional Analysis/Insights
The iron-deficiency anemia therapy market is analysed and market size insights and trends are provided by country, therapy, therapy areas, population, end-users and distribution channel as referenced above.
The countries covered in the iron-deficiency anemia therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the iron-deficiency anemia therapy market due of the region's developed healthcare system. Further accelerating the market's growth rate in this region will be the increased emphasis of the key players on novel technology.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the region's increasing healthcare costs and population, government initiatives to improve the healthcare sector, and rising demand for iron-deficiency anemia therapy.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Iron-Deficiency Anemia Therapy Market Share Analysis
The iron-deficiency anemia therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to iron-deficiency anemia therapy market.
Some of the major players operating in the iron-deficiency anemia therapy market are:
- Fresenius SE & Co. KGaA (Germany)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AbbVie Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Ireland)
- Lupin (India)
- ViforPharma Ltd. (Switzerland)
- AMAG Pharmaceuticals (U.S.)
- Akebia Therapeutics, INC. (U.S.)
- CHO-A Pharmaceutical CO., LTD. (South Korea)
- Orion Corporation (Finland)
- Pharmacosmos A/S (Denmark)
- Shield Therapeutics (U.K.)
- Advanz Pharmaceutical (U.K.)
- Alkem Labs (India)
- Zydus Cadila (India)
- Hikma Pharmaceuticals PLC (U.K.)
SKU-